Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma (Q42177470)

From Wikidata

Jump to navigation Jump to search

scientific article published on 9 May 2012

Language	Label	Description	Also known as
English	Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma	scientific article published on 9 May 2012

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

0 references

Lessons on Tumour Response: Imaging during Therapy with (177)Lu-DOTA-octreotate. A Case Report on a Patient with a Large Volume of Poorly Differentiated Neuroendocrine Carcinoma (English)

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

1 reference

based on heuristic

inferred from title

author name string

Ulrike Garske

1

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Mattias Sandström

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Silvia Johansson

3

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Dan Granberg

4

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Hans Lundqvist

5

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Mark Lubberink

6

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Anders Sundin

7

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Barbro Eriksson

8

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

publication date

9 May 2012

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

5

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

459-471

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Clinical results of radionuclide therapy of neuroendocrine tumours with 90Y-DOTATATE and tandem 90Y/177Lu-DOTATATE: which is a better therapy option?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Somatostatin-receptor-based imaging and therapy of gastroenteropancreatic neuroendocrine tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Up-regulation of somatostatin receptor density on rat CA20948 tumors escaped from low dose [177Lu-DOTA0,Tyr3]octreotate therapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Dosimetry in Peptide radionuclide receptor therapy: a review.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Practical dosimetry of peptide receptor radionuclide therapy with (90)Y-labeled somatostatin analogs.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Serum cystatin C, a new marker of glomerular filtration rate, is increased during malignant progression

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Metaiodobenzylguanidine and somatostatin in oncology: role in the management of neural crest tumours.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

131I-MIBG as a first-line treatment in high-risk neuroblastoma patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Tolerance of normal tissue to therapeutic irradiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

26 October 2017

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

29 May 2018

90Y/177Lu-DOTATATE therapy: survival of the fittest?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Individualized dosimetry in patients undergoing therapy with (177)Lu-DOTA-D-Phe (1)-Tyr (3)-octreotate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part II-specific NE tumour types

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Treatment of metastatic carcinoid tumours, phaeochromocytoma, paraganglioma and medullary carcinoma of the thyroid with (131)I-meta-iodobenzylguanidine [(131)I-mIBG].

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

[177Lu-DOTA(0),Tyr3] octreotate for somatostatin receptor-targeted radionuclide therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

A new cause of renal thrombotic microangiopathy: yttrium 90-DOTATOC internal radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

17 August 2018

Guidelines for radioiodine therapy of differentiated thyroid cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

1 December 2018

Down-regulation of the Sodium/Iodide Symporter Explains 131I-Induced Thyroid Stunning

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3360199

1 December 2018

Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Guidelines for the management of gastroenteropancreatic neuroendocrine tumours (including bronchopulmonary and thymic neoplasms). Part I-general overview

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Comparison of [(177)Lu-DOTA(0),Tyr(3)]octreotate and [(177)Lu-DOTA(0),Tyr(3)]octreotide: which peptide is preferable for PRRT?

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Minor changes in effective half-life during fractionated177Lu-Octreotate therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Improved prediction of decreased creatinine clearance by serum cystatin C: use in cancer patients before and during chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/22768026

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.7150/THNO.3594

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42177470&oldid=2249127966"